Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.55 |
| ▸ | RELA | Q04206 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10989659 | 0.89 | APP (0.61) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL15414023 | 0.86 | APP (0.71) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL30903625 | 0.86 | APP (0.71) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL25752044 | 0.83 | APP (0.55) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL19984988 | 0.83 | APP (0.77) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL3187010 | 0.81 | KDM4E (0.68) | KDM4ERAB9ANFKB1NFKB2RELA | |
| Dimethylamine SCHEMBL2524428 | 0.81 | APP (0.72) | KDM4ENFKB1NFKB2RELAHPGD | |
| SCHEMBL17404415 | 0.80 | KDM4E (0.66) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL34460069 | 0.79 | TNF (0.49) | KDM4ERAB9ANFKB1NFKB2RELA | |
| SCHEMBL2914054 | 0.79 | APP (0.66) | KDM4ERAB9ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246953-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | LG DISPLAY CO., LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-20240237519-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | LG DISPLAY CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4063368-B1 | NITROGEN-CONTAINING COMPOUND AND ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4389851-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | LG Display Co., Ltd. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118239943-A | Organic compound, organic light emitting diode having the same, and organic light emitting device | 乐金显示有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239944-A | Organic compound, organic light emitting diode having the same, and organic light emitting device | 乐金显示有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230200233-A1 | COMPOSITION, ELECTRONIC COMPOMENT AND ELECTRONIC DEVICE CONTAINING THE COMPOSITION | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200233-A1 | COMPOSITION, ELECTRONIC COMPOMENT AND ELECTRONIC DEVICE CONTAINING THE COMPOSITION | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230142329-A1 | ORGANIC LIGHT EMITTING ELEMENT | LG DISPLAY CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142329-A1 | ORGANIC LIGHT EMITTING ELEMENT | LG DISPLAY CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1996193-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| CN-101316845-A | Fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1951724-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | KDM4E 1344/4885RAB9A 223/4885NFKB1 2406/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | KDM4E 1612/4885RAB9A 720/4885NFKB1 1500/4885 |
| US-20240246953-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | TELO2, ARNT, TYR | KDM4E 1580/4885RAB9A 4231/4885NFKB1 2667/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | KDM4E 3387/4885RAB9A 564/4885NFKB1 2340/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | KDM4E 1473/4885RAB9A 1191/4885NFKB1 805/4885 |
| US-20240237519-A1 | ORGANIC COMPOUND, ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | NLRP3, NLRP1, TYR | KDM4E 1611/4885RAB9A 4296/4885NFKB1 1419/4885 |
| US-20230142329-A1 | ORGANIC LIGHT EMITTING ELEMENT | L3MBTL3, L3MBTL4, CRY2 | KDM4E 1272/4885RAB9A 3651/4885NFKB1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.